A triple-band antenna array for next-generation wireless and satellite-based applications

In this paper, a triple-band 1 × 2 and 1 × 4 microstrip patch antenna array for next-generation wireless and satellite-based applications are presented. The targeted frequency bands are 3.6, 5.2 and 6.7 GHz, respectively. Simple design procedures and optimization techniques are discussed to achieve better antenna performance. The antenna is designed and simulated using Agilent ADS Momentum using FR4 substrate (r = 4.2 and h = 1.66 mm). The main patch of the antenna is designed for 3.6 GHz operation. A hybrid feed technique is used for antenna arrays with quarter-wave transformer-based network to match the impedance from the feed-point to the antenna to 50. The antenna is optimized to resonate at triple-bands by using two symmetrical slits. The single-element triple-band antenna is fabricated and characterized, and a comparison between the simulated and measured antenna is presented. The achieved simulated impedance bandwidths/gains for the 1 × 2 array are 1.67%/7.75, 1.06%/7.7, and 1.65%/9.4 dBi and for 1 × 4 array are 1.67%/10.2, 1.45%/8.2, and 1.05%/10 dBi for 3.6, 5.2, and 6.7 GHz bands, respectively, which are very practical. These antenna arrays can also be used for advanced antenna beam-steering systems. Copyright © Cambridge University Press and the European Microwave Association 2014

Prevalence of drug-resistant Klebsiella pneumoniae in Iran: A review article

Background: The infections caused by drug resistant strains of Klebsiella pneumoniae are becoming an important health problem worldwide. There are several reports on antimicrobial resistant status of K. pneumoniae in Iran. However, a comprehensive analysis on drug-resistant K. pneumoniae from different parts of Iran has not yet been performed. Methods: The searches were done according to several English and Persian databases including PubMed, Scopus, Iranmedex, and SID to identify studies addressing antibiotic resistant K. pneumoniae in Iran from Jan 1998 to Nov 2014. Comprehensive Meta-Analysis (V2.2, Biostat) software was used to analyze the data. Results: The incidence rate of imipenem and ceftazidime resistance in K. pneumoniae isolates was 3.2 (95 confidence interval CI, 1.5-6.5) and 55.7% (95% CI, 46.9-64.1), respectively. The highest rate of resistance in isolates of K. pneumoniae was seen against ampicillin (82.2%), aztreonam (55.4%) and nitrofurantoin (54.5%). Conclusion: There is a relatively high prevalence of drug resistant K. pneumoniae isolates in Iran. Thus, a high degree of awareness among physicians and microbiologists, active infection control committee, appropriate antimicrobial therapy, improvement of hygiene condition and monitoring of drug resistant isolates are urgently needed in order to better control the emergence and spread of drug-resistant K. pneumoniae isolates in hospital settings. © 2018, Iranian Journal of Public Health. All rights reserved

A triple-band antenna array for next-generation wireless and satellite-based applications

In this paper, a triple-band 1 × 2 and 1 × 4 microstrip patch antenna array for next-generation wireless and satellite-based applications are presented. The targeted frequency bands are 3.6, 5.2 and 6.7 GHz, respectively. Simple design procedures and optimization techniques are discussed to achieve better antenna performance. The antenna is designed and simulated using Agilent ADS Momentum using FR4 substrate (r = 4.2 and h = 1.66 mm). The main patch of the antenna is designed for 3.6 GHz operation. A hybrid feed technique is used for antenna arrays with quarter-wave transformer-based network to match the impedance from the feed-point to the antenna to 50. The antenna is optimized to resonate at triple-bands by using two symmetrical slits. The single-element triple-band antenna is fabricated and characterized, and a comparison between the simulated and measured antenna is presented. The achieved simulated impedance bandwidths/gains for the 1 × 2 array are 1.67%/7.75, 1.06%/7.7, and 1.65%/9.4 dBi and for 1 × 4 array are 1.67%/10.2, 1.45%/8.2, and 1.05%/10 dBi for 3.6, 5.2, and 6.7 GHz bands, respectively, which are very practical. These antenna arrays can also be used for advanced antenna beam-steering systems. Copyright © Cambridge University Press and the European Microwave Association 2014

Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2,3,4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease

Physical properties of predicted Ti2CdN versus existing Ti2CdC MAX phase: An ab initio study

<b>Highlights</b>\ud \ud - Ti₂CdN is a predicted phase of MAX nanolaminate.\ud \ud - Physical properties have been studied for the predicted Ti₂CdN phase.\ud \ud - Physical properties of isostructural Ti₂CdC have been compared with Ti₂CdN.\ud \ud - Existing Ti₂CdC and predicted Ti₂CdN show important mechanical and optical properties.\ud \ud <b>Abstract</b>\ud \ud <i>Ab intio</i> calculations were done to investigate the structural, elastic, electronic and optical properties of the Cd-containing theoretically predicted MAX phase, Ti₂CdN, in comparison with the isostructural and already synthesized phase, Ti₂CdC. These calculations reveal that the substitution of C by N affects the lattice parameter c, whereas the lattice parameter a, remains almost unchanged. All the elastic constants and moduli increase when carbon is replaced by nitrogen. The elastic anisotropy in Ti₂CdC is higher in comparison with that of Ti₂CdN. Both these nanolaminates are brittle in nature. The calculated electronic band structures and density of states suggest that the chemical bonding in these two ternary compounds is a combination of covalent, ionic and metallic in nature. Electrical conductivity of Ti₂CdC is found to be higher than that of Ti₂CdN. The calculated reflectivity spectra show that both the MAX phases Ti₂CdC and Ti₂CdN have the potential to be used as coating materials to minimize solar heating

A Systematic Review: Burden And Severity Of Subclinical Cardiovascular Disease Among Those With Nonalcoholic Fatty Liver; Should We Care?

Background: Non-alcoholic fatty liver disease (NAFLD) is an emerging disease and a leading cause of chronic liver disease. The prevalence in the general population is approximately 15-30% and it increases to 70-90% in obese or diabetic populations. NAFLD has been linked to increased cardiovascular disease (CVD) risk. It is therefore critical to evaluate the relationship between markers of subclinical CVD and NAFLD. Method: An extensive search of databases; including the National Library of Medicine and other relevant databases for research articles meeting inclusion criteria: observational or cohort, studies in adult populations and clearly defined NAFLD and markers of subclinical CVD. Results: Twenty-seven studies were included in the review; 16 (59%) presented the association of NAFLD and carotid intima-media thickness (CIMT), 7 (26%) the association with coronary calcification and 7 (26%) the effect on endothelial dysfunction and 6 (22%) influence on arterial stiffness. CIMT studies showed significant increases among NAFLD patients compared to controls. These were independent of traditional risk factors and metabolic syndrome. The association was similar in coronary calcification studies. The presence of NAFLD is associated with the severity of the calcification. Endothelial dysfunction and arterial stiffness showed significant independent associations with NAFLD. Two studies argued the associations were not significant; however, these studies were limited to diabetic populations. Conclusion: There is evidence to support the association of NAFLD with subclinical atherosclerosis independent of traditional risk factors and metabolic syndrome. However, there is need for future longitudinal studies to review this association to ascertain causality and include other ethnic populations. © 2013 Elsevier Ireland Ltd.2302258267Adams, L.A., Angulo, P., Recent concepts in non-alcoholic fatty liver disease (2005) Diabet Med, 22 (9), pp. 1129-1133McCullough, A.J., Pathophysiology of nonalcoholic steatohepatitis (2006) JClin Gastroenterol, 40 (SUPPL.1), pp. S17-S29Marchesini, G., Marzocchi, R., Agostini, F., Bugianesi, E., Nonalcoholic fatty liver disease and the metabolic syndrome (2005) Curr Opin Lipidol, 16 (4), pp. 421-427Neuschwander-Tetri, B.A., Nonalcoholic steatohepatitis and the metabolic syndrome (2005) Am J Med Sci, 330 (6), pp. 326-335Targher, G., Arcaro, G., Non-alcoholic fatty liver disease and increased risk of cardiovascular disease (2007) Atherosclerosis, 191 (2), pp. 235-240Eckel, R.H., Grundy, S.M., Zimmet, P.Z., The metabolic syndrome (2005) The Lancet, 365 (9468), pp. 1415-1428Ndumele, C.E., Nasir, K., Conceicao, R.D., Carvalho, J.A., Blumenthal, R.S., Santos, R.D., Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation (2011) Arterioscler Thromb Vasc Biol, 31 (8), pp. 1927-1932Stefan, N., Kantartzis, K., Haring, H.U., Causes and metabolic consequences of Fatty liver (2008) Endocr Rev, 29 (7), pp. 939-960Kim, H.J., Kim, H.J., Lee, K.E., Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults (2004) Arch Intern Med, 164 (19), pp. 2169-2175Toledo, F.G., Sniderman, A.D., Kelley, D.E., Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes (2006) Diabetes Care, 29 (8), pp. 1845-1850Adiels, M., Taskinen, M.R., Boren, J., Fatty liver, insulin resistance, and dyslipidemia (2008) Curr Diab Rep, 8 (1), pp. 60-64DeFilippis, A.P., Blaha, M.J., Martin, S.S., Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis (2013) Atherosclerosis, 227 (2), pp. 429-436Targher, G., Day, C.P., Bonora, E., Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease (2010) NEngl J Med, 363 (14), pp. 1341-1350Targher, G., Bertolini, L., Padovani, R., Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients (2007) Diabetes Care, 30 (5), pp. 1212-1218Targher, G., Bertolini, L., Padovani, R., Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes (2010) JHepatol, 53 (4), pp. 713-718Stefan, N., Kantartzis, K., Machann, J., Identification and characterization of metabolically benign obesity in humans (2008) Arch Intern Med, 168 (15), pp. 1609-1616Fuchs, M., Sanyal, A.J., Lipotoxicity in NASH (2012) JHepatol, 56 (1), pp. 291-293Ridker, P.M., Rifai, N., Rose, L., Buring, J.E., Cook, N.R., Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events (2002) NEngl J Med, 347 (20), pp. 1557-1565Cesari, M., Penninx, B.W., Newman, A.B., Inflammatory markers and onset of cardiovascular events: results from the Health ABC study (2003) Circulation, 108 (19), pp. 2317-2322Thogersen, A.M., Jansson, J.H., Boman, K., High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor (1998) Circulation, 98 (21), pp. 2241-2247Stefan, N., Haring, H.U., The role of hepatokines in metabolism (2013) Nat Rev Endocrinol, 9 (3), pp. 144-152Stefan, N., Haring, H.U., The metabolically benign and malignant fatty liver (2011) Diabetes, 60 (8), pp. 2011-2017Lehmann, R., Franken, H., Dammeier, S., Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver (2013) Diabetes Care, , [Epub ahead of print]Rittig, K., Thamer, C., Haupt, A., High plasma fetuin-A is associated with increased carotid intima-media thickness in a middle-aged population (2009) Atherosclerosis, 207 (2), pp. 341-342Targher, G., Bertolini, L., Padovani, R., Zenari, L., Zoppini, G., Falezza, G., Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation (2004) Diabetes Care, 27 (10), pp. 2498-2500Brea, A., Mosquera, D., Martin, E., Arizti, A., Cordero, J.L., Ros, E., Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study (2005) Arterioscler Thromb Vasc Biol, 25 (5), pp. 1045-1050Volzke, H., Robinson, D.M., Kleine, V., Hepatic steatosis is associated with an increased risk of carotid atherosclerosis (2005) World J Gastroenterol, 11 (12), pp. 1848-1853Aygun, C., Kocaman, O., Sahin, T., Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease (2008) Dig Dis Sci, 53 (5), pp. 1352-1357Fracanzani, A.L., Burdick, L., Raselli, S., Carotid artery intima-media thickness in nonalcoholic fatty liver disease (2008) Am J Med, 121 (1), pp. 72-78McKimmie, R.L., Daniel, K.R., Carr, J.J., Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study (2008) Am J Gastroenterol, 103 (12), pp. 3029-3035Kim, H.C., Kim, D.J., Huh, K.B., Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome (2009) Atherosclerosis, 204 (2), pp. 521-525Petit, J.M., Guiu, B., Terriat, B., Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients (2009) JClin Endocrinol Metab, 94 (10), pp. 4103-4106Salvi, P., Ruffini, R., Agnoletti, D., Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study (2010) JHypertens, 28 (8), pp. 1699-1707Vlachopoulos, C., Manesis, E., Baou, K., Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: a pilot study (2010) Am J Hypertens, 23 (11), pp. 1183-1189Dogru, T., Genc, H., Tapan, S., Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease? (2012) Diabetes Res Clin Pract, 96 (1), pp. 47-52Mohammadi, A., Bazazi, A., Ghasemi-Rad, M., Evaluation of atherosclerotic findings in patients with nonalcoholic fatty liver disease (2011) Int J Gen Med, 4, pp. 717-722Colak, Y., Karabay, C.Y., Tuncer, I., Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease (2012) Eur J Gastroenterol Hepatol, 24 (6), pp. 613-618Colak, Y., Senates, E., Yesil, A., Assessment of endothelial function in patients with nonalcoholic fatty liver disease (2013) Endocrine, 43 (1), pp. 100-107Huang, Y., Bi, Y., Xu, M., Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese (2012) Arterioscler Thromb Vasc Biol, 32 (9), pp. 2321-2326Thakur, M.L., Sharma, S., Kumar, A., Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians (2012) Atherosclerosis, 223 (2), pp. 507-511Akabame, S., Hamaguchi, M., Tomiyasu, K., Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT) (2008) Circ J, 72 (4), pp. 618-625Santos, R.D., Nasir, K., Conceicao, R.D., Sarwar, A., Carvalho, J.A., Blumenthal, R.S., Hepatic steatosis is associated with a greater prevalence of coronary artery calcification in asymptomatic men (2007) Atherosclerosis, 194 (2), pp. 517-519Assy, N., Djibre, A., Farah, R., Grosovski, M., Marmor, A., Presence of coronary plaques in patients with nonalcoholic fatty liver disease (2010) Radiology, 254 (2), pp. 393-400Chen, C.H., Nien, C.K., Yang, C.C., Yeh, Y.H., Association between nonalcoholic fatty liver disease and coronary artery calcification (2010) Dig Dis Sci, 55 (6), pp. 1752-1760Kim, D., Choi, S.Y., Park, E.H., Nonalcoholic fatty liver disease is associated with coronary artery calcification (2012) Hepatology, 56 (2), pp. 605-613Jung, D.H., Lee, Y.J., Ahn, H.Y., Shim, J.Y., Lee, H.R., Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification (2010) Clin Chem Lab Med, 48 (12), pp. 1829-1834Villanova, N., Moscatiello, S., Ramilli, S., Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease (2005) Hepatology, 42 (2), pp. 473-480Senturk, O., Kocaman, O., Hulagu, S., Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease (2008) Intern Med J, 38 (3), pp. 183-189Sciacqua, A., Perticone, M., Miceli, S., Endothelial dysfunction and non-alcoholic liver steatosis in hypertensive patients (2011) Nutr Metab Cardiovasc Dis, 21 (7), pp. 485-491Mohammadi, A., Sedani, H.H., Ghasemi-Rad, M., Evaluation of carotid intima-media thickness and flow-mediated dilatation in middle-aged patients with nonalcoholic fatty liver disease (2011) Vasc Health Risk Manag, 7, pp. 661-665Isilak, Z., Aparci, M., Kardesoglu, E., Abnormal aortic elasticity in patients with liver steatosis (2010) Diabetes Res Clin Pract, 87 (1), pp. 44-50Catena, C., Bernardi, S., Sabato, N., Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension (2013) Nutr Metab Cardiovasc Dis, 23 (4), pp. 389-393Chalasani, N., Younossi, Z., Lavine, J.E., The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012) Am J Gastroenterol, 107 (6), pp. 811-826Mishra, P., Younossi, Z.M., Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD) (2007) Am J Gastroenterol, 102 (12), pp. 2716-2717Brea, A., Puzo, J., Non-alcoholic fatty liver disease and cardiovascular risk (2012) Int J Cardiol, , [Epub ahead of print]Kim, B.J., Kim, N.H., Kim, B.S., Kang, J.H., The association between nonalcoholic fatty liver disease, metabolic syndrome and arterial stiffness in nondiabetic, nonhypertensive individuals (2012) Cardiology, 123 (1), pp. 54-61Cobble, M., Bale, B., Carotid intima-media thickness: knowledge and application to everyday practice (2010) Postgrad Med, 122 (1), pp. 10-18Hamirani, Y.S., Pandey, S., Rivera, J.J., Markers of inflammation and coronary artery calcification: a systematic review (2008) Atherosclerosis, 201 (1), pp. 1-7Braun, J., Oldendorf, M., Moshage, W., Heidler, R., Zeitler, E., Luft, F.C., Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients (1996) Am J Kidney Dis, 27 (3), pp. 394-401O'Malley, P.G., Taylor, A.J., Jackson, J.L., Doherty, T.M., Detrano, R.C., Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations (2000) Am J Cardiol, 85 (8), pp. 945-948Sangiorgi, G., Rumberger, J.A., Severson, A., Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology (1998) JAm Coll Cardiol, 31 (1), pp. 126-133Arad, Y., Spadaro, L.A., Goodman, K., Predictive value of electron beam computed tomography of the coronary arteries. 19-Month follow-up of 1173 asymptomatic subjects (1996) Circulation, 93 (11), pp. 1951-1953Desai, C.S., Ning, H., Kang, J., Competing cardiovascular outcomes associated with subclinical atherosclerosis (from the multi-ethnic study of atherosclerosis) (2013) Am J Cardiol, 111 (11), pp. 1541-1546Gorgui, J., Doonan, R.J., Gomez, Y.H., Kwong, C., Daskalopoulou, S.S., Carotid endarterectomy improves peripheral but not central arterial stiffness (2013) Eur J Vasc Endovasc Surg, 45 (6), pp. 548-553Vlachopoulos, C., Aznaouridis, K., Stefanadis, C., Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis (2010) JAm Coll Cardiol, 55 (13), pp. 1318-1327Bhatia, L.S., Curzen, N.P., Calder, P.C., Byrne, C.D., Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? (2012) Eur Heart J, 33 (10), pp. 1190-1200Sookoian, S., Pirola, C.J., Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review (2008) JHepatol, 49 (4), pp. 600-607Bhatia, L.S., Curzen, N.P., Byrne, C.D., Nonalcoholic fatty liver disease and vascular risk (2012) Curr Opin Cardiol, 27 (4), pp. 420-428Kopec, K.L., Burns, D., Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy (2011) Nutr Clin Pract, 26 (5), pp. 565-576Ruhl, C.E., Everhart, J.E., Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States (2003) Gastroenterology, 124 (1), pp. 71-79Pagano, G., Pacini, G., Musso, G., Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association (2002) Hepatology, 35 (2), pp. 367-372Sanyal, A.J., Campbell-Sargent, C., Mirshahi, F., Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities (2001) Gastroenterology, 120 (5), pp. 1183-1192Choi, S.Y., Kim, D., Kim, H.J., The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans (2009) Am J Gastroenterol, 104 (8), pp. 1953-1960Targher, G., Bertolini, L., Poli, F., Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients (2005) Diabetes, 54 (12), pp. 3541-3546Targher, G., Marra, F., Marchesini, G., Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? (2008) Diabetologia, 51 (11), pp. 1947-1953Sung, K.C., Wild, S.H., Kwag, H.J., Byrne, C.D., Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people (2012) Diabetes Care, 35 (11), pp. 2359-2364Targher, G., Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens (2007) Diabet Med, 24 (1), pp. 1-6McCullough, A.J., The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease (2004) Clin Liver Dis, 8 (3), pp. 521-533. , viiiRacial/ethnic and socioeconomic disparities in multiple risk factors for heart disease and stroke - United States, 2003 (2005) MMWR Morb Mortal Wkly Rep, 54 (5), pp. 113-117Mensah, G.A., Mokdad, A.H., Ford, E.S., Greenlund, K.J., Croft, J.B., State of disparities in cardiovascular health in the United States (2005) Circulation, 111 (10), pp. 1233-1241Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., Marchesini, G., Aposition statement on NAFLD/NASH based on the EASL 2009 special conference (2010) JHepatol, 53 (2), pp. 372-384Friedrich-Rust, M., Schlueter, N., Smaczny, C., Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis (2013) JCyst Fibros, , [Epub ahead of print]Ferdinand, K.C., Coronary artery disease in minority racial and ethnic groups in the United States (2006) Am J Cardiol, 97 (2 A), pp. 12A-19ABrowning, J.D., Szczepaniak, L.S., Dobbins, R., Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity (2004) Hepatology, 40 (6), pp. 1387-1395Liu, J., Fox, C.S., Hickson, D., Bidulescu, A., Carr, J.J., Taylor, H.A., Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study (2011) Arterioscler Thromb Vasc Biol, 31 (11), pp. 2715-2722Nestel, P.J., Mensink, R.P., Perspective: nonalcoholic fatty liver disease and cardiovascular risk (2013) Curr Opin Lipidol, 24 (1), pp. 1-

Changes in Coronary Plaque Volume: Comparison of Serial Measurements on Intravascular Ultrasound and Coronary Computed Tomographic Angiography

Cardiovascular Aspects of Radiolog